MX2017015582A - Metodos y composiciones para tratamiento guiado por arn de infeccion por vih. - Google Patents
Metodos y composiciones para tratamiento guiado por arn de infeccion por vih.Info
- Publication number
- MX2017015582A MX2017015582A MX2017015582A MX2017015582A MX2017015582A MX 2017015582 A MX2017015582 A MX 2017015582A MX 2017015582 A MX2017015582 A MX 2017015582A MX 2017015582 A MX2017015582 A MX 2017015582A MX 2017015582 A MX2017015582 A MX 2017015582A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- rna
- methods
- hiv infection
- guided treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen composiciones para escindir específicamente secuencias objetivo en retrovirus, que incluyen ácidos nucleicos que codifican una endonucleasa asociada con la Repetición Palindrómica Corta Agrupada y Regularmente Interespaciada (CRISPR), y una secuencia de ARN guiada complementaria a una o más secuencias de ácido nucleico objetivo en un genoma retrovírico.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562169384P | 2015-06-01 | 2015-06-01 | |
US201562169633P | 2015-06-02 | 2015-06-02 | |
US201662308320P | 2016-03-15 | 2016-03-15 | |
PCT/US2016/035141 WO2016196539A2 (en) | 2015-06-01 | 2016-06-01 | Methods and compositions for rna-guided treatment of hiv infection |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017015582A true MX2017015582A (es) | 2018-09-06 |
Family
ID=57442165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015582A MX2017015582A (es) | 2015-06-01 | 2016-06-01 | Metodos y composiciones para tratamiento guiado por arn de infeccion por vih. |
Country Status (16)
Country | Link |
---|---|
US (3) | US11298410B2 (es) |
EP (2) | EP3302709B1 (es) |
JP (1) | JP6968416B2 (es) |
KR (2) | KR20230110368A (es) |
CN (1) | CN108025188A (es) |
AU (2) | AU2016270702B2 (es) |
CA (1) | CA2987927C (es) |
DK (1) | DK3302709T3 (es) |
EA (1) | EA037359B1 (es) |
ES (1) | ES2886480T3 (es) |
HK (1) | HK1253882A1 (es) |
MX (1) | MX2017015582A (es) |
PL (1) | PL3302709T3 (es) |
SG (1) | SG10201914137YA (es) |
WO (1) | WO2016196539A2 (es) |
ZA (1) | ZA201708236B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9925248B2 (en) | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
JP6968416B2 (ja) | 2015-06-01 | 2021-11-17 | テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Rna誘導性の、hiv感染の処置のための、方法および組成物 |
AU2016332345A1 (en) * | 2015-09-28 | 2018-04-12 | Temple University - Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
IL294014B1 (en) | 2015-10-23 | 2024-03-01 | Harvard College | Nucleobase editors and their uses |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR20190130613A (ko) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
WO2018194876A1 (en) * | 2017-04-17 | 2018-10-25 | Temple University- Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
CA3111479A1 (en) * | 2017-09-26 | 2019-04-04 | The Board Of Trustees Of The University Of Illinois | Crispr/cas system and method for genome editing and modulating transcription |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
WO2020150499A1 (en) * | 2019-01-16 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to tag and isolate cells infected with the human immunodeficiency virus |
EP3942040A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CN115279898A (zh) * | 2019-10-23 | 2022-11-01 | 成对植物服务股份有限公司 | 用于植物中rna模板化编辑的组合物和方法 |
EP4114952A4 (en) * | 2020-03-05 | 2024-05-08 | Board of Regents of the University of Nebraska | CRISPR/CAS9 SYSTEM FOR THE TREATMENT OF MULTI-STRAIN HIV-1 |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
CN112322587A (zh) * | 2020-09-17 | 2021-02-05 | 杭州市第一人民医院 | 一种带Cas9基因的人源可诱导多能干细胞系、构建方法、鉴定方法及应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
WO2014165349A1 (en) * | 2013-04-04 | 2014-10-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
US9925248B2 (en) | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
CN103923911B (zh) * | 2014-04-14 | 2016-06-08 | 上海金卫生物技术有限公司 | CRISPR-Cas9特异性敲除人CCR5基因的方法以及用于特异性靶向CCR5基因的sgRNA |
CN104480144B (zh) | 2014-12-12 | 2017-04-12 | 武汉大学 | 用于艾滋病基因治疗的CRISPR/Cas9重组慢病毒载体及其慢病毒 |
JP6968416B2 (ja) * | 2015-06-01 | 2021-11-17 | テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Rna誘導性の、hiv感染の処置のための、方法および組成物 |
AU2016332345A1 (en) | 2015-09-28 | 2018-04-12 | Temple University - Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
JP2018531261A (ja) | 2015-10-16 | 2018-10-25 | テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Cpf1を用いた、rnaガイド遺伝子編集方法および組成物 |
WO2017100431A2 (en) | 2015-12-09 | 2017-06-15 | Excision Biotherapeutics, Inc. | Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy |
US9925425B2 (en) | 2016-03-17 | 2018-03-27 | Acushnet Company | Golf ball incorporating at least three adjacent ionomeric and/or HNP-based layers having multiple related property gradients there between |
WO2017176529A1 (en) | 2016-04-06 | 2017-10-12 | Temple Univesity-Of The Commonwealth System Of Higher Education | Compositions for eradicating flavivirus infections in subjects |
WO2017192172A1 (en) | 2016-05-05 | 2017-11-09 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided eradication of varicella zoster virus |
US20190256844A1 (en) | 2016-06-07 | 2019-08-22 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided compositions for preventing and treating hepatitis b virus infections |
US20190085326A1 (en) | 2016-09-14 | 2019-03-21 | Temple University - Of The Commonwealth System Of Higher Education | Negative feedback regulation of HIV-1 by gene editing strategy |
WO2018071623A2 (en) | 2016-10-12 | 2018-04-19 | Temple University - Of The Commonwealth System Of Higher Education | Combination therapies for eradicating flavivirus infections in subjects |
US11299430B2 (en) | 2016-11-30 | 2022-04-12 | Hrl Laboratories, Llc | Formulations with active functional additives for 3D printing of preceramic polymers, and methods of 3D-printing the formulations |
US20180208914A1 (en) | 2017-01-26 | 2018-07-26 | Excision Biotherapeutics, Inc. | Lentivirus and non-integrating lentivirus as viral vector to deliver crispr therapeutic |
WO2018152418A1 (en) | 2017-02-17 | 2018-08-23 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
WO2018194876A1 (en) | 2017-04-17 | 2018-10-25 | Temple University- Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
-
2016
- 2016-06-01 JP JP2017562290A patent/JP6968416B2/ja active Active
- 2016-06-01 CA CA2987927A patent/CA2987927C/en active Active
- 2016-06-01 SG SG10201914137YA patent/SG10201914137YA/en unknown
- 2016-06-01 EP EP16804274.5A patent/EP3302709B1/en active Active
- 2016-06-01 AU AU2016270702A patent/AU2016270702B2/en active Active
- 2016-06-01 KR KR1020237022586A patent/KR20230110368A/ko active Application Filing
- 2016-06-01 PL PL16804274T patent/PL3302709T3/pl unknown
- 2016-06-01 WO PCT/US2016/035141 patent/WO2016196539A2/en active Application Filing
- 2016-06-01 EP EP21172750.8A patent/EP3919622A1/en active Pending
- 2016-06-01 DK DK16804274.5T patent/DK3302709T3/da active
- 2016-06-01 CN CN201680045342.2A patent/CN108025188A/zh active Pending
- 2016-06-01 US US15/578,372 patent/US11298410B2/en active Active
- 2016-06-01 KR KR1020177037584A patent/KR102553518B1/ko active IP Right Grant
- 2016-06-01 MX MX2017015582A patent/MX2017015582A/es unknown
- 2016-06-01 ES ES16804274T patent/ES2886480T3/es active Active
- 2016-06-01 EA EA201890012A patent/EA037359B1/ru unknown
-
2017
- 2017-12-04 ZA ZA2017/08236A patent/ZA201708236B/en unknown
-
2018
- 2018-10-11 HK HK18113022.5A patent/HK1253882A1/zh unknown
-
2020
- 2020-05-15 US US16/875,271 patent/US11273209B2/en active Active
- 2020-09-10 US US17/017,037 patent/US20210052709A1/en active Pending
-
2022
- 2022-03-17 AU AU2022201875A patent/AU2022201875A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11298410B2 (en) | 2022-04-12 |
WO2016196539A3 (en) | 2017-02-16 |
EP3302709B1 (en) | 2021-05-19 |
JP2018516572A (ja) | 2018-06-28 |
SG10201914137YA (en) | 2020-02-27 |
EP3919622A1 (en) | 2021-12-08 |
AU2016270702A1 (en) | 2017-12-21 |
US20200282025A1 (en) | 2020-09-10 |
PL3302709T3 (pl) | 2021-12-06 |
KR20230110368A (ko) | 2023-07-21 |
JP6968416B2 (ja) | 2021-11-17 |
ZA201708236B (en) | 2019-12-18 |
US11273209B2 (en) | 2022-03-15 |
EA037359B1 (ru) | 2021-03-17 |
EA201890012A1 (ru) | 2018-05-31 |
EP3302709A2 (en) | 2018-04-11 |
CA2987927A1 (en) | 2016-12-08 |
KR102553518B1 (ko) | 2023-07-07 |
HK1253882A1 (zh) | 2019-07-05 |
WO2016196539A2 (en) | 2016-12-08 |
CN108025188A (zh) | 2018-05-11 |
DK3302709T3 (da) | 2021-08-23 |
US20180296649A1 (en) | 2018-10-18 |
EP3302709A4 (en) | 2019-01-23 |
CA2987927C (en) | 2024-03-19 |
ES2886480T3 (es) | 2021-12-20 |
US20210052709A1 (en) | 2021-02-25 |
AU2016270702B2 (en) | 2022-01-20 |
AU2022201875A1 (en) | 2022-04-07 |
KR20180023911A (ko) | 2018-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017015582A (es) | Metodos y composiciones para tratamiento guiado por arn de infeccion por vih. | |
WO2017058658A3 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
MX2016002586A (es) | Métodos y composiciones para el tratamiento guiado por rna de infección por hiv. | |
WO2017213898A3 (en) | Rna guided compositions for preventing and treating hepatitis b virus infections | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
WO2019006471A3 (en) | NOVEL CRISPR RNA TARGETING ENZYMES, SYSTEMS AND USES THEREOF | |
MX2020011939A (es) | Nuevas enzimas y sistemas crispr. | |
RU2022103603A (ru) | Направляемые нуклеиновыми кислотами нуклеазы | |
MX2017005672A (es) | Erradicacion guiada de arn de virus jc mano y otros poliomavirus. | |
WO2017100431A3 (en) | Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy | |
EP4349404A3 (en) | Respiratory virus vaccines | |
MX2018005392A (es) | Acidos nucleicos modificados dirigidos a acidos nucleicos. | |
WO2016086177A3 (en) | Compositions and methods for hiv quasi-species excision from hiv-1-infected patients | |
EP3382019A4 (en) | METHOD OF CONVERTING A MONOCOTE PLANT GENOME SEQUENCE SPECIFICALLY CONVERTING A NUCLEIC ACID BASIS IN TARGETED DNA SEQUENCE AND MOLECULAR COMPLEX THEREOF | |
MX2017011829A (es) | Edicion de genes basada en repeticiones palindromicas cortas agrupadas y regularmente interespaciadas (crispr)/endonucleasa inducida por tat. | |
MX2016011686A (es) | Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc). | |
WO2011147590A8 (en) | Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains | |
PT3216867T (pt) | Método para modificar a sequência de genoma para introduzir mutação específica a sequência de adn alvo por reação de remoção de bases, e complexo molecular nele utilizado | |
RU2016104056A (ru) | Мультиплексная геномная инженерия, направляемая рнк | |
WO2015200555A3 (en) | Rna modification to engineer cas9 activity | |
MX2019006475A (es) | Sistemas y métodos para dirección con arn guía puntual (arngp) de adn endógeno y fuente. | |
MD4760C8 (ro) | Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D | |
WO2015042308A3 (en) | Rna-based hiv inhibitors | |
PH12019550255A1 (en) | Compositions and methods for increasing shelf-life of banana | |
MX2018005872A (es) | Profarmacos de acido nucleico. |